To overcome this limitation, researchers have instead focused on targets upstream of c-Myc, such as BET bromodomain inhibitors [40], which have demonstrated preclinical efficacy in models of c-Myc-driven CRPC and shown considerable promise as a therapy for PCa [41]. This evidence concerns the gene DNER and posterior cortical atrophy.